ArticleClinical and translational radiation oncology2026
Simultaneous integrated boost vs sequential boost chemoradiotherapy in anal squamous cell carcinoma: Association with improved disease-free survival and the role of treatment delivery parameters.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose.The optimal radiotherapy delivery strategy for anal canal cancer remains debated. We compared outcomes between simultaneous integrated boost (SIB) and sequential boost approaches in patients treated with chemoradiotherapy. Materials and methods: This single-centre retrospective study included consecutive patients with localised or locally advanced anal canal squamous cell carcinoma treated with volumetric modulated arc therapy between June 2019 and July 2024. All patients received 60 Gy to the primary tumour and involved lymph nodes. Prophylactic nodal irradiation was delivered either sequentially (44 Gy in 22 fractions) or with SIB (45 Gy in 30 fractions). The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and treatment-related adverse events (CTCAE v5.0). Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Cox models were used for multivariable analysis. Results: Eighty-four patients were included: 50 treated with SIB and 34 with a sequential approach.Median follow-up from the end of radiotherapy was 21 and 48 months in the SIB and sequential groups, respectively. The 24-month DFS rate was 96% in the SIB group versus 70% in the sequential group. SIB was independently associated with improved DFS (HR 0.12, 95% CI 0.03-0.53; Conclusion: SIB-based radiotherapy was associated with improved DFS without increasing the rate of treatment-related adverse events. This benefit may be partly related to shorter overall treatment time and potential immune-sparing effects. Longer follow-up and prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.